At the news
? NEUTRALIMPACT 5/10 PRESS-RELEASE filed May 13, 2026 at 07:00 ET
PDS Biotech reported Q1 2026 net loss of $7.3M ($0.13/share), narrower than the $8.5M loss ($0.21/share) in Q1 2025, driven by lower R&D and G&A expenses. The EPS of -$0.13 beat the consensus estimate of -$0.14 by 7.1%, but the company remains a pre-revenue clinical-stage biotech with no approved products and a cash runway of $21.7M. The key catalyst is the amended VERSATILE-003 Phase 3 trial protocol incorporating PFS as an interim endpoint, which could enable an accelerated approval pathway for PDS0101 in head and neck cancer.
- Q1 2026 net loss of $7.3M ($0.13/share) vs $8.5M ($0.21/share) in Q1 2025
- EPS of -$0.13 beat consensus estimate of -$0.14 by 7.1%
- Cash balance of $21.7M as of March 31, 2026, down from $26.7M at year-end 2025
- Amended VERSATILE-003 Phase 3 trial to include PFS as interim primary endpoint, potentially enabling accelerated approval for PDS0101
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access